CanSense

CanSense is developing a rapid, inexpensive, and scalable blood diagnostic test for the early diagnosis of bowel cancer using AI-based modeling. This test is a potential game-changer in the methods for diagnosing and screening bowel cancer. It focuses on patient acceptability and reducing mortality through early diagnosis. An additional benefit is the reduction in the need for more invasive colonoscopy diagnostics, alleviating the financial burden on healthcare providers.